Bladder cancer data disappoint shareholders looking for signs of dose response and differentiation from Valstar.
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
Nerlynx succeeds in a new breast cancer setting, but this might amount to little more than a win on a technicality.